Cumberland Pharmaceuticals Inc. (CPIX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CPIX Revenue Growth
Revenue Breakdown (FY 2025)
CPIX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
CPIX Revenue Analysis (2014–2025)
As of May 8, 2026, Cumberland Pharmaceuticals Inc. (CPIX) generated trailing twelve-month (TTM) revenue of $41.9 million, reflecting significant decline in growth of -22.0% year-over-year. The most recent quarter (Q1 2026) recorded $9.1 million in revenue, down 33.2% sequentially.
Looking at the longer-term picture, CPIX's 5-year compound annual growth rate (CAGR) stands at +3.5%, indicating moderate growth over time. The company achieved its highest annual revenue of $44.5 million in 2025, representing a new all-time high.
Revenue diversification analysis shows CPIX's business is primarily driven by Product (75%), Product - Vibativ (18%), and Product - Other (8%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including HROW (+36.4% YoY), PRPH (-91.6% YoY), and AYTU (-3.3% YoY), CPIX has underperformed the peer group in terms of revenue growth. Compare CPIX vs HROW →
CPIX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CPIXCurrent | $42M | -22.0% | +3.5% | -6.3% | |
 HROW | $272M | +36.4% | +41.0% | 11.2% | |
 PRPH | $7M | -91.6% | -7.3% | -570.6% | |
 AYTU | $66M | -3.3% | +19.2% | -11.8% | |
 CODA | $27M | +33.2% | +5.8% | 17.1% | |
 AMRX | $3.0B | +8.0% | +8.7% | -0.2% |
CPIX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $44.5M | +17.6% | $37.9M | 85.0% | $-2,791,993 | -6.3% |
| 2024 | $37.9M | -4.3% | $31.3M | 82.6% | $-6,432,409 | -17.0% |
| 2023 | $39.6M | -5.9% | $33.5M | 84.7% | $-9,554,661 | -24.2% |
| 2022 | $42.0M | +16.7% | $32.9M | 78.3% | $-5,704,929 | -13.6% |
| 2021 | $36.0M | -3.9% | $27.2M | 75.5% | $-7,677,420 | -21.3% |
| 2020 | $37.4M | +8.9% | $28.8M | 76.9% | $-6,381,595 | -17.0% |
| 2019 | $34.4M | -15.6% | $27.0M | 78.4% | $-9,288,182 | -27.0% |
| 2018 | $40.7M | -1.0% | $33.4M | 81.9% | $-7,390,772 | -18.1% |
| 2017 | $41.2M | +24.6% | $33.8M | 82.1% | $-4,081,348 | -9.9% |
| 2016 | $33.0M | -1.5% | $27.1M | 82.0% | $-1,433,131 | -4.3% |
See CPIX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CPIX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CPIX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCPIX — Frequently Asked Questions
Quick answers to the most common questions about buying CPIX stock.
Is CPIX's revenue growth accelerating or slowing?
CPIX revenue declined -22.0% year-over-year, contrasting with the 5-year CAGR of +3.5%. TTM revenue fell to $42M. This reverses the prior growth trend.
What is CPIX's long-term revenue growth rate?
Cumberland Pharmaceuticals Inc.'s 5-year revenue CAGR of +3.5% reflects the variable expansion pattern. Current YoY growth of -22.0% is below this long-term average.
How is CPIX's revenue distributed by segment?
CPIX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.